{"disease":{"id":"squamous-cell-non-small-cell-lung-cancer","name":"squamous cell non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06255197","title":"Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03199651","title":"Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":3584,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04205812","title":"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":583,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT01673867","title":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":582,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02409342","title":"A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06319313","title":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05010330","title":"Identify Prognostic Biomarkers of Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Allist Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02193282","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":390,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04439890","title":"A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":369,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04977453","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT04181060","title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01642004","title":"Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT05429463","title":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03645928","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Iovance Biotherapeutics, Inc.","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT03829501","title":"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":222,"lead_sponsor_name":"Kymab Limited","has_results":true},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04171284","title":"SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT07169734","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Alentis Therapeutics AG","has_results":false},{"nct_id":"NCT03761017","title":"MGD019 DART® Protein in Unresectable/Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT07405086","title":"Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04262856","title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT07503808","title":"A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT03729596","title":"MGC018 With or Without MGA012 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT03110978","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04490564","title":"Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Pharmassist Ltd","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT05962021","title":"Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":126,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04310007","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01721759","title":"Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03421912","title":"Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06690216","title":"Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100,"lead_sponsor_name":"Man Hu","has_results":false},{"nct_id":"NCT04844073","title":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":95,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05360381","title":"HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03621982","title":"Study of ADCT-301 in Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":true},{"nct_id":"NCT04916002","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05267470","title":"A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}